300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Egypt
Gibraltar
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Oman
Poland
Puerto Rico
Andorra
Guernsey
Cameroon
Sudan
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Ireland
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Global Asset Fund, VC Fund

Global Asset Fund

VC Fund

Landshut, Germany

Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.

Total investments:
9
Last investment:
Lead investor:
11%

Last updated:

Industries Global Asset Fund invests in

BiotechnologyMedicalHealth CareTherapeuticsManufacturing

Stages Global Asset Fund invests in

Series ASeries BFunding RoundVenture - Series Unknown

Countries Global Asset Fund invests in

GermanyAustria

Round sizes

Series A $1M–$1.9MSeries B $1.6M–$2.8M

Round size

Series A
$1M–$1.9M
Series B
$1.6M–$2.8M

Investment Focus

Industry

  • Biotechnology 2 (22%)
  • Medical 1 (11%)
  • Health Care 1 (11%)
  • Therapeutics 1 (11%)
  • Manufacturing 1 (11%)
See all 7 industries →

Stage

  • Series A 1 (11%)
  • Series B 1 (11%)
  • Funding Round 1 (11%)
  • Venture - Series Unknown 1 (11%)

Country

  • Germany 2 (22%)
  • Austria 1 (11%)

Investments

CompanyDescriptionRoundLinks
Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, andanalysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably. Venture - Series Unknown / Sep 01, 2019
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. $2.8M / Series B / Mar 23, 2017
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. $1.7M / Series B / Apr 15, 2016
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. $1.6M / Series B / May 15, 2015
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. $1M / Series A / Jun 30, 2014
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. $7.6M / Apr 24, 2014
SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials. $1.9M / Series A / Apr 13, 2013
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. $8.8M / Jul 07, 2011
Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. $14.3M / Mar 15, 2010

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
LATAM
Egypt
Gibraltar
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Oman
Poland
Puerto Rico
Andorra
Guernsey
Cameroon
Sudan
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Ireland
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Slovenia
Peru
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Global Asset Fund invest in?

Global Asset Fund invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Global Asset Fund's check size?

Global Asset Fund typically joins rounds of $1M–$1.9M at Series A and $1.6M–$2.8M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Global Asset Fund participates in.

When did Global Asset Fund last invest?

The most recent investment recorded for Global Asset Fund closed in Sep 2019. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Global Asset Fund Global Asset Fund Find emails